Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer
about
ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistanceThe minority report: targeting the rare oncogenes in NSCLCCrizotinib in ROS1-rearranged non-small-cell lung cancer.Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALKAn Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.Activation of RAS family members confers resistance to ROS1 targeting drugs.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer.Resisting Resistance: Targeted Therapies in Lung Cancer.Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.Detecting and targetting oncogenic fusion proteins in the genomic era.Recent Advances in Targeting ROS1 in Lung Cancer.Emerging targeted therapies in non-small cell lung cancer.Histopathologic diagnosis of brain metastases: current trends in management and future considerations.Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer.ROS1 fusions in cancer: a review.Resistance to Therapy.Downregulation of ROS-FIG inhibits cell proliferation, colony‑formation, cell cycle progression, migration and invasion, while inducing apoptosis in intrahepatic cholangiocarcinoma cells.An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations.Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of ResistanceTargeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer.Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review.Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance.Understanding and targeting resistance mechanisms in NSCLC.EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer.Genomic Profiling on an Unselected Solid Tumor Population Reveals a Highly Mutated Wnt/β-Catenin Pathway Associated with Oncogenic EGFR Mutations.Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastomaCombined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusionsPersonalized therapy for lung cancer: Striking a moving target
P2860
Q26775347-146EF800-8CEA-4905-A89D-BA9F611C25BFQ26851636-5C06BDFF-1C36-4CD6-B592-1D13DEA279B2Q27853075-3ABE618F-572B-49A1-B6C4-6FB3C3EC1A71Q28083446-21EE0C8F-1971-4A2D-B7E9-FB0A09AFF4DEQ28265615-C223B671-34A6-4A28-80BE-B5AB6224E625Q34158153-672A4C1C-D2F5-4491-996D-ADB3FA8E88E5Q34431889-C279F8AD-831D-4E2E-914D-F75A9CDABB20Q34463388-542E0F5A-B4EA-430F-B7A7-EE08D803AA69Q35136424-A1C6BF42-70E8-4722-893B-AF653131F2A3Q36860098-9FFCD22B-C5D8-434B-863C-BC99A43A85C7Q37388238-912BF2A9-2AC3-49BF-8571-BB19C1E42335Q38213830-90178D77-07EC-4AB5-8A55-E17BC0BEAC8DQ38336067-221AE523-08C1-4C20-88C5-7E9B1A948383Q38640765-484D4DEF-422C-4F0A-91AF-11B8A1E91B79Q38653045-670D9128-301F-487C-BCB5-722EF4A266F1Q38791747-F61BFCFB-A338-4883-95FF-10F3D15021BEQ38792120-4437B153-4C12-48DA-9CB8-91610393FFE5Q38852070-9264DC34-2ACF-47FB-97B5-DE12E8861324Q38930367-7FBAC700-CD5F-4B7D-8314-630CC49C20BAQ38980941-EBAF73E7-9E1A-4FED-B4F2-2070B0848B96Q39859110-4E93FA8E-C0F7-4B52-BB4B-E70F7A7C7C41Q40406762-59D44371-B926-43EA-A27A-88BBFA594233Q42292974-970EE2CD-2037-45C0-A23F-DFCA166793C9Q42369856-39F8504B-3385-4DF9-8EEB-E7D765BE5D99Q44507827-D7196AFB-68AF-46FD-89D9-7E11DCCEE4ECQ46071509-4A047894-F389-4BC1-8BF3-7DFA0EAD8051Q46915997-507AC5B5-8E95-4995-B10F-BCA62D43BD92Q47137989-BDBD88B8-1581-461E-84D0-7AF79528B9DBQ47351169-C8C51B7F-78BB-409E-86C1-109919CCF3E1Q48179589-EDE8BB51-A04A-4481-80B4-CE5DEC7ED2C1Q50251062-A47279D9-0657-4E04-958D-DD1AAB512BF5Q51004850-4C76919C-0360-4F95-B70A-E446C3A0C4F0Q52720230-A69A3BF0-CAF7-4D7B-9BF1-C853E48494B6Q55457466-EDDFD8B7-2BEA-4E48-A6F3-6FBA85C9AF02Q58698690-28978BE4-8107-40F3-9B4E-B03286DFC0A6Q58749346-02E65763-02C8-41B0-A5CF-5389B77F667BQ58792324-E2EC3F68-F514-45C3-9044-D270B1F77E33
P2860
Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Resistance to ROS1 inhibition ...... in non-small cell lung cancer
@ast
Resistance to ROS1 inhibition ...... in non-small cell lung cancer
@en
Resistance to ROS1 inhibition ...... in non-small cell lung cancer
@nl
type
label
Resistance to ROS1 inhibition ...... in non-small cell lung cancer
@ast
Resistance to ROS1 inhibition ...... in non-small cell lung cancer
@en
Resistance to ROS1 inhibition ...... in non-small cell lung cancer
@nl
prefLabel
Resistance to ROS1 inhibition ...... in non-small cell lung cancer
@ast
Resistance to ROS1 inhibition ...... in non-small cell lung cancer
@en
Resistance to ROS1 inhibition ...... in non-small cell lung cancer
@nl
P2093
P2860
P1433
P1476
Resistance to ROS1 inhibition ...... in non-small cell lung cancer
@en
P2093
Aria Vaishnavi
D Ross Camidge
Dara L Aisner
David P Astling
Kurtis D Davies
Lynn E Heasley
Marileila Varella-Garcia
Paul A Bunn
Robert C Doebele
P2860
P304
P356
10.1371/JOURNAL.PONE.0082236
P407
P577
2013-12-13T00:00:00Z